Drug
Lifileucel
Lifileucel: highest development phase Phase 2, developed by Iovance Biotherapeutics. 7 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Iovance Biotherapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lifileucel NCT06481592 | Phase 2 | Endometrial Cancer |
| Lifileucel NCT07741877 | Phase 2 | Sarcoma |
| Lifileucel NCT03645928 | Phase 2 | Metastatic Melanoma |
| Lifileucel NCT07288203 | Phase 2 | Melanoma (Skin Cancer) |
| Lifileucel NCT02360579 | Phase 2 | Metastatic Melanoma |
| Lifileucel (LN-144) NCT05640193 | Phase 1 | Metastatic Melanoma |
| Lifileucel (LN-144/LN-145) NCT05607095 | Phase 1 | Uveal Melanoma |
Latest
No recent events.
Follow Lifileucel on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.